Alcon Posts Strong Q4 Growth as IOL Portfolio Surpasses 175 Million Implants Worldwide

Alcon has closed out 2025 on a high note, reporting fourth-quarter net sales of US$2.7 billion, up 9% on a reported basis and 7% in constant currency compared to the same period last year, while simultaneously announcing a landmark milestone for its intraocular lens (IOL) portfolio.

The Geneva-headquartered eye care giant confirmed this week that more than 175 million of its IOLs have been implanted globally since 1993, a figure that underscores the company's dominant position in the cataract surgery market. Embedded within that number are more than six million presbyopia-correcting IOL (PCIOL) implants, with PanOptix and Vivity leading the field in the trifocal and extended depth of focus (EDOF) categories respectively.

Financial Highlights

For the full year 2025, Alcon recorded net sales of US$10.3 billion, up 5% on a reported basis. Free cash flow came in at US$1.7 billion, and the company returned US$848 million to shareholders through buybacks and dividends.

Within the Surgical segment full-year implantables net sales held steady at US$1.8 billion, reflecting the US rollout of PanOptix Pro alongside what the company described as "soft market conditions and competitive pressures," particularly in international markets. Consumables grew 6% to US$3.0 billion, driven by vitreoretinal procedural volume and price increases.

In Q4 specifically, surgical equipment and other products surged 21% (18% constant currency) to US$277 million, led by the recently launched Unity platform.

Looking ahead, Alcon has guided for 2026 net sales growth of 5–7% in constant currency, with core diluted EPS growth of 9–12%. The company flagged a potential full-year tariff headwind of US$125–175 million, net of mitigating actions, as a key variable to watch.

IOL Milestone: PanOptix Crosses Four Million Implants

PanOptix, first implanted in 2015 by Professor Thomas Kohnen at Goethe University in Frankfurt, has now surpassed four million implants worldwide — cementing its position as the world's most widely implanted trifocal IOL. Patient satisfaction data cited by Alcon shows 99% of PanOptix recipients would choose the same lens again.

The lens received the "Best Medical Technology" award at the 50th Prix Galien USA in 2021, and in 2025 Alcon extended the platform with the launch of Clareon PanOptix Pro. It is now available in the US, Canada, Japan, Australia and New Zealand. The Pro variant offers 94% light utilisation compared to 88% for the original PanOptix, effectively halving light scatter and delivering improved image contrast across the full visual range.

"PanOptix Pro builds on that legacy with an advanced optical design delivering less light scatter and better image contrast," said Dr Neda Shamie of the Maloney-Shamie-Hura Vision Institute in Los Angeles, notably adding that she selected PanOptix and Vivity for her own parents' cataract surgeries.

Vivity Crosses Two Million Implants

Alcon's Vivity, the first non-diffractive EDOF IOL, has exceeded two million implants. Designed for patients who are either unsuitable for diffractive optics or have demanding visual lifestyles such as frequent night driving, Vivity provides glasses-free distance and intermediate vision with a clinically demonstrated low rate of visual disturbances.

South Korean ophthalmologist Dr Jiwon Jeong, who has conducted comparative studies of Vivity against newer EDOF competitors, highlighted the lens's consistent performance across a broad range of patient profiles over time as a key differentiator in her practice.

What's Next

Alcon has indicated it plans to launch additional IOL technologies in key markets later in 2026, subject to regulatory approvals. The company is also midway through an operational efficiency program expected to deliver approximately US$100 million in run-rate savings, with around US$50 million of that benefit expected to flow through in the current financial year.

For Australian eyecare professionals, the availability of PanOptix Pro represents the most immediate clinical development to note. The company's guidance for continued product innovation in the PCIOL space signals further options may be on the horizon for surgeons and their patients.